Cited by 474Pharmaceutical Economics and PolicyPharmaceutical industry and healthcareHistorical Medical Research and Treatments

The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.

Pharmaceutical innovation by the seven UK‐owned pharmaceutical companies (1964‐1985).

Open access

Prentis, RA, Lis, Y, Walker, SR·1988·British Journal of Clinical Pharmacology

DOI 10.1111/j.1365-2125.1988.tb03318.xPMC PMC1386364

Open this paper in CoChat — free account Open PDF

Abstract

1 A total of three hundred and nineteen new chemical entities (NCEs) were investigated in man for the first time between 1964 and 1985 by seven UK‐owned pharmaceutical companies. The majority (96.2%), were self‐originated by the UK company or one of its overseas subsidiaries. 2 There was an increase in the number of NCEs investigated each year in man, doubling from an average of 12 per year up to 1980, to over 20 per year between 1981 and 1985. The majority of first drug evaluations in human volunteers were carried out in the UK (92.2%), in contrast to evaluation of new medicines in patients, where 42.9% were first tested outside the UK. 3 The majority of NCEs evaluated in man (78%), were in four therapeutic classes: anti‐infectives (32%), anti‐allergics (22%), drugs acting on the central nervous system (13%) and cardiovascular system agents (11%). 4 By the end of 1985, 49 (15.4%) of these NCEs had been marketed in the UK and 198 (62.0%) discontinued from further development. The main reasons for termination were inappropriate pharmacokinetics in man (39.4%), and lack of clinical efficacy (29.3%). 5 Average development times increased from less than 2 years between 1964 and 1965, to around 8 years in the 1980s with a consequent reduction in the effective patent life.

Integrity signals

Registry

Crossref · 10.1111/j.1365-2125.1988.tb03318.x

Cites

12 of 12 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

New drug development in the United States, 1963 through 1984
Mattison, N., Trimble, A. G., & Lasagna, L. C. (1988) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.1988.35 · Cited by 53
Drug innovation—what's slowing it down?
Steward, F., & Wibberley, G. (1980) · Nature · doi:10.1038/284118a0 · Cited by 44
The rate of development of new drugs in the United States, 1963 through 1975
Wardell, W. M., Hassar, M., & Anavekar, S. N. (1978) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt1978242133 · Cited by 32
A survey of products licensed in the United Kingdom from 1971‐1981.
Griffin, J. L., & Diggle, G. E. (1981) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1981.tb01251.x · Cited by 27
The Measurement of Pharmaceutical Innovation
Wardell, W. M., & DiRaddo, J. (1980) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1980.tb01660.x · Cited by 21
Pharmaceuticals in seven nations
Chew, R., Smith, G. T., & Wells, N. E. J. (1985) · Monographs · Cited by 18
Trends in the development of new medicines by UK‐owned pharmaceutical companies (1964‐1980).
Prentis, R., & Walker, S. (1986) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1986.tb05219.x · Cited by 16
Self-citation
A survey of the first year of operation of the new procedure affecting the conduct of clinical trials in the United Kingdom.
Speirs, C., & Griffin, J. P. (1983) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1983.tb01545.x · Cited by 15
Is pharmaceutical innovation declining?: interpreting measures of pharmaceutical innovation and regulatory impact in the USA, 1950-1980.
Wardell, W. M., & Le, S. (1983) · PubMed · Cited by 10
The development of self-originated new drugs by Swiss pharmaceutical firms, 1960–1980
Mattison, N., Thomas, E., Trimble, A. G., & Wardell, W. M. (1984) · Regulatory Toxicology and Pharmacology · doi:10.1016/0273-2300(84)90038-2 · Cited by 10

Show all 12 references

Research works printed but not linked: 7

Hass A. E., 1985, New drugs: Their market life and safety, Pharm. J., 234, 235
Lumley C. E., 1987, Trends in research and development expenditure by the UK pharmaceutical industry (1982–84), Pharm. Med.
Reis‐Arndt E., 1975, New pharmaceutical agents 1961–1973, Drugs made in Germany, 18, 123
Reis‐Arndt E., 1982, 20 Jahre Arzneimittelentwick — lung — Neue pharmazeutische Wirkstoffe 1961–1980, Pharmac. Ind., 44, 1115
Speirs C. J. Saunders R. M.&Griffin J. P.(1984).The UK Clinical Trial Exemption scheme — its effects on investment in researchPharm. Int. Oct. 254–256.
Walker S. R., 1982, Innovation and drug development — Can the process be expedited, BIRA Journal, 1, 34
Walker S. R., 1985, Drug Research & Pharmaceutical Patents, Pharm. J., 234, 11

Sorted by citations

Items 401–474 of 474

AIM in Pharmacology and Drug Discovery
Iwata, H., Kojima, R., & Okuno, Y. (2021) · Springer eBooks · doi:10.1007/978-3-030-58080-3_145-1 · Cited by 1
On the Border Between Chemistry and Technology - Nanotechnology and other Industrial Applications of Supramolecular Systems
(2002) · Springer eBooks · doi:10.1007/0-306-47587-1_6 · Cited by 1
Pharmacodynamic Effects of an Angiotensin II Receptor-Antagonist in Phase I—Comparison between Healthy Subjects and Patients with Hypertension
Wensing, G., Ochmann, K., Böettcher, M., Schäfer, A., & Kuhlmann, J. (2007) · Biomarker Insights · doi:10.1177/117727190700200039 · Cited by 1
Drug Administration
Sim, D. S. M. (2014) · Springer eBooks · doi:10.1007/978-3-319-10386-0_2 · Cited by 1
FORMULATION AND EVALUATION OF RIVAROXABAN IMMEDIATE RELEASE TABLETS
Prasanna, M. L., Prajna, P., Chinnari, P., Anusha, P., Harshini, P. N. R. S., & Ratna, P. V. L. S. (2022) · International Journal of Research in Pharmacy and Chemistry · doi:10.33289/ijrpc.12.2.2022.12(20 · Cited by 1
FORMULATION DEVELOPMENT, OPTIMIZATION & IN VITRO CHARATERIZATION OF LIQUISOLID COMPACTS OF AN OXICAM DERIVATIVE
Kapoor, D. U., Patel, M. P., Vyas, R. B., & Lad, C. (2016) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v6i3.1263 · Cited by 1
AIM in Pharmacology and Drug Discovery
Iwata, H., Kojima, R., & Okuno, Y. (2022) · Springer eBooks · doi:10.1007/978-3-030-64573-1_145 · Cited by 1
The GSK Bioanalytical Hub Model in Bioanalysis: Maximizing the Synergies of Co-Locating Various Platforms in Support of Regulated and Nonregulated Study end Points
Summerfield, S. G., Tang, H., Decman, V., Abberley, L., Gunn, G. R., & Yang, E. (2023) · Bioanalysis · doi:10.4155/bio-2022-0180 · Cited by 1
In situ forming hydrogels for intra-articular delivery of celecoxib: from polymer design to in vivo studies
Petit, A. (2014) · Utrecht University Repository (Utrecht University) · Cited by 1
Toxicogenomics: Applications to In Vivo Toxicology
Semizarov, D., & Blomme, E. A. G. (2008) · Wiley eBooks · doi:10.1002/9780470409770.ch5 · Cited by 1
Strategies in Lead Selection and Optimization: Application of a Graphical Model and Automated In Vitro ADME Screening
Mandagere, A. K. (2002) · Springer eBooks · doi:10.1007/978-3-662-04383-7_9 · Cited by 1
A Pharmacokinetics and Pharmacodynamics (PK/PD) Guided Approach to Lead Optimization of Nitrofuranylamide Anti-Tuberculosis Agents
Budha, N. R. (2009) · doi:10.21007/etd.cghs.2009.0039 · Cited by 1
Alternate Methods for Assessing Absorption, Metabolism, and Routes of Elimination
Bullock, P. L. (2005) · Drugs and the pharmaceutical sciences · doi:10.1201/9780849360237.ch9 · Cited by 1
ADME Profiling
Mertsch, K., Will, M., Czechtizky, W., Griesang, N., Marker, A., & Olsen, J. (2015) · doi:10.1002/9781118771723.ch13 · Cited by 1
Validation of In Vitro Methods for Toxicology Studies
Stokes, W. (2006) · CRC Press eBooks · doi:10.1201/b14139-10 · Cited by 1
Novel drugs for tuberculosis: pharmacological and biochemical characterization in suitable test systems
Wanas, H. (2012) · Digitale Bibliothek Braunschweig (Verbundzentrale Göttingen (VZG)) · doi:10.24355/dbbs.084-201301091143-0 · Cited by 1
Introduction
Davis, C. B. (2009) · doi:10.1002/9780470574898.ch1 · Cited by 1
Design and Synthesis of Hepatitis C Virus NS3 Protease Inhibitors
Johansson, A. (2003) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 1
Pharmacodynamic Effects of an Angiotensin II Receptor-Antagonist in Phase I-Comparison between Healthy Subjects and Patients with Hypertension.
Wensing, G., Ochmann, K., Böettcher, M., Schäfer, A., & Kuhlmann, J. (2007) · PubMed Central · Cited by 1
In-Silico ADME Modeling
Matter, H., & Schmider, W. (2013) · Springer eBooks · doi:10.1007/978-3-642-25240-2_45
A RECENT APPROACH FOR SOLUBILITY AND BIOAVAILABILITY ENHANCEMENT: SOLID DISPERSION
Patel Chirag, J. (2013) · Journal of Drug Discovery and Therapeutics
High Throughput Quantitative Mass Spectrometry
Williams, J. D., & Grant, R. P. (2012) · Encyclopedia of Drug Metabolism and Interactions · doi:10.1002/9780470921920.edm110
Accelerator Mass Spectrometry and Positron Emission Tomography in Human Microdosing
Cheng, Z. (2011) · Wiley eBooks · doi:10.1002/9780470571224.pse429
In vitro and in silico Predictions of Hepatic Transporter-Mediated Drug Clearance and Drug-Drug Interactions in vivo
Vildhede, A. M. (2015) · KTH Publication Database DiVA (KTH Royal Institute of Technology)
BJCP 40th anniversary: moving forward, looking back
Gilchrist, A., Loke, Y. K., Somogyi, A. A., Cohen, A. F., & Ritter, J. M. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12520
Interrelationship between Pharmacokinetics and Metabolism
Paxton, J. W. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse060
Die post-SELEX Optimierung des Trypanosomen-spezifischen RNA-Aptamers 2-16
Adler, A. (2008) · Technischen Universität Darmstadt · doi:10.26083/tuprints-00000892
Catechol O-Methyltransferase : Glucuronidation of Inhibitors and Methylation of Substrates
Lautala, P. (2000) · Työväentutkimus Vuosikirja
New product development (NPD)
Mehta, S. S. (2008) · Cambridge University Press eBooks · doi:10.1017/cbo9780511791345.006
THE IN VITRO METABOLISM OF THREE ANTICANCER DRUGS
Fan, Y. (2007) · D-Scholarship@Pitt (University of Pittsburgh)
ADVERSE EVENT REPORTING FOR A FOOD EFFECT BIOAVAILABILITY STUDY OF ROXITHROMYCIN
Chaudhari, R. Y., & Nagar, T. (2014)
ASSESSMENT OF PHARMACOKINETIC INTERACTION OF L-DOPA AND BENSERAZIDE
Fakultät, P.-N., & Grange, S. S. (2004)
FACULDADE DE CIÊNCIAS FARMACÊUTICAS Programa de Pós-Graduação em Fármaco e Medicamentos Área de Produção e Controle Farmacêuticos Sistema de Classificação Biofarmacêutica e Bioisenções
Bonamici, D. (2009)
Genome Sequencing and Genomic Technologies in Drug Discovery and Development
Gelbert, L. M. (2003) · doi:10.1007/978-1-59259-346-0_13
Bioinformatic studies of the disposition pathways and targets of synthetic drugs and herbal medicines
Di, Y. (2012) · RMIT Research Repository (RMIT University Library) · doi:10.25439/rmt.27332868
Epidemiology of Cytochrome P450-mediated Drug-Drug Interactions
Tirkkonen, T. (2010) · UTUPub (University of Turku)
UNIVERSIDADE FEDERAL DE SANTA CATARINA CENTRO DE CIÊNCIAS BIOLÓGICAS PROGRAMA DE PÓS-GRADUAÇÃO EM FARMACOLOGIA MESTRADO PROFISSIONAL EM FARMACOLOGIA AVALIAÇÃO DA FARMACOCINÉTICA DA COMBINAÇÃO SULFAMETOXAZOL + TRIMETOPRIMA EM RATOS COMO FERRAMENTA PREDITIVA DE ESTUDOS DE BIOEQUIVALÊNCIA/BIODISPONIBILIDADE RELATIVA EM
Humanos, S. (2011)
Clinical Dose and Nontoxic Dose in Repeated Administration of a Variety of Drugs in Relation to Their Pharmacokinetics.
Kato, R. (1993) · Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics · doi:10.3999/jscpt.24.595
Bio-functionalisation of polyelectrolyte microcapsules with biotinylated poly (ethylene glycol)- grafted liposomes for application in targeted drug delivery
Gao, J. (2012) · doi:10.32657/10356/50619
Development of injectable pH-degradable polymeric particles containing thrombin for minimally invasive delivery of fibrin glue to the heart post-myocardial infraction
Chagar, S. S. (2014) · eScholarship (California Digital Library)
Attrition in Phase I
Smith, D. A., & Baillie, T. A. (2015) · Wiley eBooks · doi:10.1002/9781118819586.ch3
Designing Combinatorial Libraries for Efficient Screening
Manchester, J. I., & Hartsough, D. S. (2003) · Humana Press eBooks · doi:10.1385/1-59259-285-6:307
Gene Expression-Based Biomarkers of Drug Safety
Blomme, E. A. G., & Warder, S. E. (2008) · Methods in pharmacology and toxicology · doi:10.1007/978-1-59745-463-6_2
Metabolism of Lignans in Schisandrae Fructus
Cao, Y. (2014) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789814635936_0005
Contemporary Considerations for Discovering a Successful Medicine
Hann, M. M., Bayliss, M. K., & Leach, A. R. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12310-8
Integrated Lead Optimization: Translational Models as We Advance Toward the Clinic
Liederer, B. M., Liu, X., Wong, S. G. W., & Mudra, D. R. (2017) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-50042-3_6
Planejamento e validação anti-proliferativa e anti-leishmania, de novos híbridos tri-funcionalizados unidos através do anel 1,2,3-triazol e compostos similares
Federico, L. B. (2017) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.59.2017.tde-03022017-141932
Lead Molecule Selection: Pharmaceutical Proﬁling and Toxicity Assessments
Bullock, P. L. (2016) · CRC Press eBooks · doi:10.3109/9781420084733-5
Pharmacokinetics/ADME of Small Molecules
Ajavon, A., & Taft, D. R. (2016) · CRC Press eBooks · doi:10.3109/9781420084733-7
DISSOLUTION RATE ENHANCEMENT OF FEBUXOSTAT BY LIQUISOLID TECHNIQUE
Patel, D., Kushwaha, A. S., & Bhalala, A. J. (2019) · International Research Journal of Pharmacy · doi:10.7897/2230-8407.1009265
A Strategy to Find Novel Candidate DKAs Inhibitors Using Modified QSAR Model with Favorable Druggability Properties
Zhang, X., Niu, W., Tang, T., Hou, C., Guo, Y., & Kong, R. (2019) · Chemical Research in Chinese Universities · doi:10.1007/s40242-019-9183-5
Assessing Pharmacokinetics of Various Dosage Forms at Early Stage
Bonsmann, S., & Ossig, J. (2019) · Methods and principles in medicinal chemistry · doi:10.1002/9783527812172.ch7
Preclinical Formulation Assessment of NCEs
Saka, R., Sathe, P., Khan, W., & Dubey, S. (2019) · Methods and principles in medicinal chemistry · doi:10.1002/9783527812172.ch4
Discovery to development: bioanalytical considerations that can facilitate the transition
Clark, G. T. (2014) · doi:10.4155/fseb2013.13.5
Speeding up the Development of 5-[(4-Chlorophenoxy)-Methyl]-1,3,4-Oxadiazole-2-Thiol as Successful Oral Drug Candidate Based on Physicochemical Characteristics
Shehzadi, N., Hussain, K., Bukhari, N. I., Islam, M. F., Salman, M., & Khan, M. T. (2020) · Pharmaceutical Chemistry Journal · doi:10.1007/s11094-020-02101-5
Planejamento computacional e avaliação in vitro de novos potenciais inibidores da fosfomanose isomerase (PMI) de interesse para o controle do cancro cítrico
Barcelos, M. P. (2020) · doi:10.11606/d.59.2020.tde-04062020-141501
Dialysis method development to assess reversibility of cytochrome P450 inhibition in vitro
Lähdeniemi, V. (2021) · Työväentutkimus Vuosikirja
The Apparent Declining Efficiency of Drug Discovery
Trist, D. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.02476-8
In vitro ADME and in vivo pharmacokinetics
Blass, B. E. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817214-8.00006-3
Introduction
Bullock, P. (2005) · CRC Press eBooks · doi:10.1201/9780849360237-13
Introduction
Subrahmanyam, V. V., & Tonelli, A. P. (2005) · CRC Press eBooks · doi:10.1201/9780849360237-8
Delineating Potential de novo Therapeutics and Repurposed Drugs Against Novel Protein LRRC15 to Treat SARS-CoV-2
Zinnia, M. A., & Islam, A. B. M. M. K. (2023) · Letters in Drug Design & Discovery · doi:10.2174/1570180820666230223120829
In-Vivo Study of Dipyridamole Liquisolid Compacts
(2023) · Journal of Population Therapeutics and Clinical Pharmacology · doi:10.47750/jptcp.2023.30.13.004
New 3-[(tetrazol-5-yl)methine-N-benzylamine)]-1H-indole derivatives: Synthesis, anti-HIV activity and molecular docking studiesPreprint
Tukulula, M., Ragedi, M. T. C., Naidu, D., Oyeneyin, O. E., & Mkhwanazi, N. P. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5272105
In Life Behavior of Praziquantel and Relationship Between Drug Exposure and Effect
Njoroge, M., & Ballard, P. G. (2025) · Springer eBooks · doi:10.1007/978-3-031-97397-0_7
In vitro anti-glucocorticoid osteoporosis effect of Serfurosterone A and its intestinal absorption characteristics
Dong, J., Yang, L., Xue, J., Gao, S., Sun, Y., Zhang, X., & Yang, L. (2025) · Xenobiotica · doi:10.1080/00498254.2025.2574899
Optimisation du processus de développement du médicament grâce à la modélisation PK et les simulations d’études cliniques
Colucci, P. (2010) · doi:10.71781/4667
Optimisation de méthodes de criblage virtuel et synthèse de molécules à visée thérapeutique pour le traitement des maladies auto-immunes.
Nasr, N. B. (2014) · theses.fr (ABES) · doi:10.70675/de51bc89z33fez456fz9467z959329cc603b
BindingDB Entry 50044110: Agonists for the adenosine A1 receptor with tunable residence time. A Case for nonribose 4-amino-6-aryl-5-cyano-2-thiopyrimidines.
BindingDB (2015) · UC San Diego · doi:10.7270/q27p90x6
BindingDB Entry 50042081: Transport characteristics of fexofenadine in the Caco-2 cell model.
BindingDB (2013) · UC San Diego · doi:10.7270/q2m909x4
BindingDB Entry 50045935: The development, characterization, and application of an OATP1B1 inhibition assay in drug discovery.
BindingDB (2016) · UC San Diego · doi:10.7270/q2zw1nn1
BindingDB Entry 50046523: Structure-kinetics relationships of Capadenoson derivatives as adenosine A1 receptor agonists.
BindingDB (2016) · UC San Diego · doi:10.7270/q2fx7c8r
BindingDB Entry 50015214: Novel cyclooxygenase-1 inhibitors discovered using affinity fingerprints.
BindingDB (2009) · UC San Diego · doi:10.7270/q24x578j
Metabolic Concerns in Drug Design
Jones, J. P. (2008) · Springer eBooks · doi:10.1007/978-0-387-77300-1_1

Authors: Prentis, R., Lis, Y., & Walker, Sr.
Venue: British Journal of Clinical Pharmacology
Publisher: Wiley
Published: 1988-03
Volume: 25
Issue: 3
Pages: 387-396
ISSN: 0306-5251 (ISSN-L)
1365-2125
DOI: 10.1111/j.1365-2125.1988.tb03318.x
PMC: PMC1386364
OpenAlex: W2117753715
Cited by: 471
References: 12
Citations by year: 2025: 8 · 2024: 7 · 2023: 11 · 2022: 16 · 2021: 12 · 2020: 10 · 2019: 14 · 2018: 13 · 2017: 17 · 2016: 16 · 2015: 23 · 2014: 22 · 2013: 21 · 2012: 24
FWCI: 8.40
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: onlinelibrary.wiley.com/termsAndConditions#vor (vor, 8913 d)
Locations: British Journal of Clinical Pharmacology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
Keywords: pharmaceutical innovation, new chemical entities, drug development, drug development time, patent life, drug discontinuation, anti-infective agents, antiallergic drugs, central nervous system drugs, cardiovascular drugs
MeSH terms: Chemistry, Pharmaceutical, Drug Industry, United Kingdom, Humans, Research

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pharmaceutical innovation by the seven UK‐owned pharmaceutical companies (1964‐1985).

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks